BioCentury | Oct 23, 2020
Emerging Company Profile

Be Bio: bringing the B to cell therapy

...someday will look like the T cell therapy landscape.”Also participating in the series A round were Alta Partners...
...Research InstituteCorporate partners: NoneNumber of employees: 10Funds raised: $52 millionInvestors: Atlas Venture, RA Capital Management, Alta Partners...
BioCentury | Jun 18, 2020
Emerging Company Profile

Lassen emerges from Frazier with over $31M and a mAb for fibrosis and cancer

...In August, Frazier led Lassen Therapeutics’ $31 million series A round, which had participation from Alta Partners...
...Holdings Corp. (Tokyo:4901) Number of employees: 8 Funds raised: $31.5 million Investors: Frazier Healthcare Partners, Alta Partners...
BioCentury | Jan 14, 2020
Finance

Tyra raises $50M series A for cancer drug resistance

...million series A round to bring its first therapy to the clinic for drug-resistant cancer. Alta Partners...
BioCentury | Jan 8, 2020
Financial News

Novome raises $33M series A, shoots for the gut with engineered microbes

...and more product development.” Seed investor 5AM Ventures also participated in the round, as did Alta Partners...
BioCentury | Nov 8, 2019
Financial News

eGenesis pushes to bring pig organ transplants to humans with $100M series B

...and Wellington Partners also participated, as did existing investors including Arch Venture Partners, Biomatics Capital, Alta Partners...
BioCentury | Aug 5, 2019
Clinical News

Big gain for Allakos as first-in-class GI program heads toward pivotal phase

...for $2.7 billion in 2015 (see “AZ Scoops Up ZS” ). During his tenure at Alta Partners...
BioCentury | Oct 19, 2018
Finance

CuraSen’s SPARK

...Venture Partners led the round, which closed on Oct. 17. Funds managed by Tekla Capital, Alta Partners...
BioCentury | Oct 19, 2018
Financial News

Led by ex-Afferent execs, CuraSen raises $54.5M series A

...by New Leaf Venture Partners. Also participating were Longitude Capital, funds managed by Tekla Capital, Alta Partners...
BioCentury | Oct 17, 2018
Financial News

Led by ex-Afferent execs, CuraSen raises $54.5M series A

...by New Leaf Venture Partners. Also participating were Longitude Capital, funds managed by Tekla Capital, Alta Partners...
BioCentury | Aug 31, 2018
Financial News

Sutro proposes $75M IPO

...for ovarian and endometrial cancer. Other shareholders with stakes greater than 5% in Sutro include Alta Partners...
Items per page:
1 - 10 of 429
BioCentury | Oct 23, 2020
Emerging Company Profile

Be Bio: bringing the B to cell therapy

...someday will look like the T cell therapy landscape.”Also participating in the series A round were Alta Partners...
...Research InstituteCorporate partners: NoneNumber of employees: 10Funds raised: $52 millionInvestors: Atlas Venture, RA Capital Management, Alta Partners...
BioCentury | Jun 18, 2020
Emerging Company Profile

Lassen emerges from Frazier with over $31M and a mAb for fibrosis and cancer

...In August, Frazier led Lassen Therapeutics’ $31 million series A round, which had participation from Alta Partners...
...Holdings Corp. (Tokyo:4901) Number of employees: 8 Funds raised: $31.5 million Investors: Frazier Healthcare Partners, Alta Partners...
BioCentury | Jan 14, 2020
Finance

Tyra raises $50M series A for cancer drug resistance

...million series A round to bring its first therapy to the clinic for drug-resistant cancer. Alta Partners...
BioCentury | Jan 8, 2020
Financial News

Novome raises $33M series A, shoots for the gut with engineered microbes

...and more product development.” Seed investor 5AM Ventures also participated in the round, as did Alta Partners...
BioCentury | Nov 8, 2019
Financial News

eGenesis pushes to bring pig organ transplants to humans with $100M series B

...and Wellington Partners also participated, as did existing investors including Arch Venture Partners, Biomatics Capital, Alta Partners...
BioCentury | Aug 5, 2019
Clinical News

Big gain for Allakos as first-in-class GI program heads toward pivotal phase

...for $2.7 billion in 2015 (see “AZ Scoops Up ZS” ). During his tenure at Alta Partners...
BioCentury | Oct 19, 2018
Finance

CuraSen’s SPARK

...Venture Partners led the round, which closed on Oct. 17. Funds managed by Tekla Capital, Alta Partners...
BioCentury | Oct 19, 2018
Financial News

Led by ex-Afferent execs, CuraSen raises $54.5M series A

...by New Leaf Venture Partners. Also participating were Longitude Capital, funds managed by Tekla Capital, Alta Partners...
BioCentury | Oct 17, 2018
Financial News

Led by ex-Afferent execs, CuraSen raises $54.5M series A

...by New Leaf Venture Partners. Also participating were Longitude Capital, funds managed by Tekla Capital, Alta Partners...
BioCentury | Aug 31, 2018
Financial News

Sutro proposes $75M IPO

...for ovarian and endometrial cancer. Other shareholders with stakes greater than 5% in Sutro include Alta Partners...
Items per page:
1 - 10 of 429